Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.
Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F. Machado-Neto JA, et al. Cell Death Dis. 2018 Feb 22;9(3):311. doi: 10.1038/s41419-017-0256-4. Cell Death Dis. 2018. PMID: 29472557 Free PMC article.
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.
Scopim-Ribeiro R, Machado-Neto JA, Eide CA, Coelho-Silva JL, Fenerich BA, Fernandes JC, Scheucher PS, Savage Stevens SL, de Melo Campos P, Olalla Saad ST, de Carvalho Palma L, de Figueiredo-Pontes LL, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. Scopim-Ribeiro R, et al. Among authors: de figueiredo pontes ll. Invest New Drugs. 2021 Jun;39(3):736-746. doi: 10.1007/s10637-020-01028-8. Epub 2021 Jan 6. Invest New Drugs. 2021. PMID: 33403501
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells.
Vicari HP, Coelho-Silva JL, Pereira-Martins DA, Lucena-Araujo AR, Lima K, Lipreri da Silva JC, Scheucher PS, Koury LC, de Melo RA, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, de Figueiredo-Pontes LL, Costa-Lotufo LV, Rego EM, Traina F, Machado-Neto JA. Vicari HP, et al. Among authors: de figueiredo pontes ll. Invest New Drugs. 2022 Apr;40(2):438-452. doi: 10.1007/s10637-021-01197-0. Epub 2021 Nov 27. Invest New Drugs. 2022. PMID: 34837603
Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors.
de Almeida FC, Berzoti-Coelho MG, Toro DM, Cacemiro MDC, Bassan VL, Barretto GD, Garibaldi PMM, Palma LC, de Figueiredo-Pontes LL, Sorgi CA, Faciolli LH, Gardinassi LG, de Castro FA. de Almeida FC, et al. Among authors: de figueiredo pontes ll. Front Immunol. 2022 Apr 13;13:840173. doi: 10.3389/fimmu.2022.840173. eCollection 2022. Front Immunol. 2022. PMID: 35493444 Free PMC article.
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
de Castro FA, Mehdipour P, Chakravarthy A, Ettayebi I, Loo Yau H, Medina TS, Marhon SA, de Almeida FC, Bianco TM, Arruda AGF, Devlin R, de Figueiredo-Pontes LL, Chahud F, da Costa Cacemiro M, Minden MD, Gupta V, De Carvalho DD. de Castro FA, et al. Among authors: de figueiredo pontes ll. Br J Haematol. 2024 Jan;204(1):206-220. doi: 10.1111/bjh.19107. Epub 2023 Sep 19. Br J Haematol. 2024. PMID: 37726227
Telomeric repeat-containing RNA is dysregulated in acute myeloid leukemia.
Catto LFB, Zanelatto LC, Donaires FS, de Carvalho VS, Santana BA, Pinto AL, Fantacini D, de Souza LEB, Fonseca NP, Telho BS, Ayrosa Madeira MI, Barbosa Pagnano KB, Firmato AB, Fagundes EM, Higashi M, Nunes EC, Traina F, Lobo de F Pontes L, Rego EM, Calado RT. Catto LFB, et al. Blood Adv. 2023 Nov 28;7(22):7067-7078. doi: 10.1182/bloodadvances.2023010658. Blood Adv. 2023. PMID: 37773887 Free PMC article.
28 results